In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 13 of 13

TitleConsultationTypeConsultation end date
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Draft guidanceTechnology appraisal guidance
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Final draft guidanceTechnology appraisal guidance
Secukinumab for treating relapsed polymyalgia rheumatica ID6599Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]Draft guidanceTechnology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Draft guidanceTechnology appraisal guidance
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]Final draft guidanceTechnology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Topical tapinarof for treating mild to severe plaque psoriasis ID6712Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Draft guidanceTechnology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All